Showing 651 results for the keyword: Leukemia
Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem
cells) have been used with varying degrees of success as an immune therapy for blood-system
cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some
people s cancer rem...
Allogeneic hematopoetic stem cell transplantation (SCT) is frequently complicated by life
threatening viral reactivation. Conventional antiviral therapy is suboptimal for
cytomegalovirus (CMV), adenovirus (AdV) and Epstein-Barr virus (EBV) and nonexistent for BK
virus (BKV). An alternative approach to pr...
-Acute myeloid leukemia (AML) is a cancer of the white blood cells. It can be fatal.
Standard treatment involves intensive chemotherapy. Not all treatment works. AML that has
not responded to treatment (refractory) or that has returned after treatment (relapsed) is
high-risk even with ...
- Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma)
for a variety of reasons, including genetic predisposition to these cancers,
environmental exposures or other medical conditions.
- Studies of people and families at high risk of c...
The development of new technologies now allow scientists to investigate the molecular basis
and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic
leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom
This study is to determine the response to acalabrutinib in patients with chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This phase II trial studies how well targeted therapy works in treating patients with acute
lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of
improvement or does not respond to treatment. Testing patients' blood or bone marrow to find
out if their type of cancer ma...
Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL
responds to rituximab, which is not yet standard therapy for HCL.
Patients with the CD25-negative variant (HCLv) respond poorly to initial cladribine but do
respond to rituximab in anecdotal rep...
- Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that
has not responded well to or has recurred after standard HCL therapies. One nonstandard
treatment for HCL is rituximab, an antibody that binds to the cancer cells and helps
This phase II trial studies how well ibrutinib works in treating patients with hairy cell
leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.